Belly dancer syndrome improved by withdrawal of droxidopa and amantadine. [PDF]
Clin Case Rep, 2023 A man hospitalized for cerebral infarction developed drug‐induced belly dancer syndrome, which improved after withdrawal of droxidopa and amantadine. Drugs that modulate dopamine neurotransmission have been reported to be associated with this syndrome ...
Kaga M +6 more
europepmc +7 more sources
Multitargeted docking approach reveals droxidopa against DNA replication and repair-related protein of cervical cancer. [PDF]
Sci RepCervical cancer begins in the cells lining the cervix and is caused by persistent infection with certain types of human papillomavirus (HPV). Initially, it has no symptoms, and later it causes pelvic pain, abnormal vaginal bleeding, and pain during ...
Alsaiari AA +9 more
europepmc +4 more sources
Use of droxidopa for blood pressure augmentation after acute spinal cord injury: case reports. [PDF]
Acute Crit Care, 2022 Hypotension secondary to autonomic dysfunction is a common complication of acute spinal cord injury (SCI) that may worsen neurologic outcomes. Midodrine, an enteral α-1 agonist, is often used to facilitate weaning intravenous (IV) vasopressors, but its ...
Hong CS +11 more
europepmc +5 more sources
Droxidopa for Management of Chronic Hypotension in Hemodialysis. [PDF]
Kidney Int RepJayanti A, Elewa M.
europepmc +5 more sources
Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review. [PDF]
Cureus, 2023 Neurogenic orthostatic hypotension (nOH) is a disabling problem of autonomic dysfunction in patients with Parkinson’s disease, which is associated with poor quality of life and higher mortality rates.
Hoxhaj P +12 more
europepmc +4 more sources
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report [PDF]
Journal of Medical Case Reports, 2020 Background Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been shown to be useful predominantly with neurogenic orthostatic hypotension secondary to Parkinson’s disease ...
Annie H. Ho +4 more
semanticscholar +4 more sources
Journal of Market Access & Health Policy, 2022 Background Symptoms of neurogenic orthostatic hypotension (nOH), including lightheadedness/dizziness, presyncope, syncope, and falls, can lead to impaired functional ability and reduced quality of life.
C. François +5 more
semanticscholar +3 more sources
L-DOPA and Droxidopa: From Force Field Development to Molecular Docking into Human β2-Adrenergic Receptor. [PDF]
Life (Basel), 2022 The increasing interest in the molecular mechanism of the binding of different agonists and antagonists to β2-adrenergic receptor (β2AR) inactive and active states has led us to investigate protein–ligand interactions using molecular docking calculations.
Catte A, Biswas AD, Mancini G, Barone V.
europepmc +4 more sources
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment [PDF]
Neurological Therapeutics, 2022 Introduction Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa are needed. We have evaluated
R. Hauser +6 more
semanticscholar +2 more sources
Copper oxide, ionic liquid and Mn(III) Salen modified carbon paste electrode as selective electrochemical sensor for determination of droxidopa in the presence of carbidopa [PDF]
, 2020 A novel electrochemical sensor for the selective and sensitive detection of droxidopa in presence of carbidopa at physiological pH was developed by the bulk modification of carbon paste electrode (CPE) with copper oxide (CuO), ionic liquid and Mn (III ...
Mohammad Reza Aflatoonian +5 more
semanticscholar +2 more sources